Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A 24-Week, Randomised, Open-label, parallel group study to compare Extended-Release Injectable Suspension and Oral Naltrexone along with Behavioral Therapy in patients with Opioid Use Disorder

Trial Profile

A 24-Week, Randomised, Open-label, parallel group study to compare Extended-Release Injectable Suspension and Oral Naltrexone along with Behavioral Therapy in patients with Opioid Use Disorder

Completed
Phase of Trial: Phase IV

Latest Information Update: 29 Oct 2018

At a glance

  • Drugs Naltrexone (Primary) ; Naltrexone
  • Indications Opioid abuse
  • Focus Therapeutic Use
  • Most Recent Events

    • 29 Oct 2018 New trial record
    • 19 Oct 2018 Primary endpoint (Retention (time to dropout) of participants across the two treatment arms during 24weeks of treatment) has been met, according to the results published in the American Journal of Psychiatry
    • 19 Oct 2018 Results published in the American Journal of Psychiatry
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top